# Biotech
New compound destroys breast cancer
ERX-41 has been shown to kill all types of breast cancer cells and other forms of human cancerous tumors.Photo byAngiola Harry on UnsplashonUnsplash. A newly created compound, ERX-41, has been found to kill a wide range of hard-to-treat types of cancers.
The Biggest Reason Why Lab-Grown Meat Won't Match Real Steaks
Why can’t we 3D print a steak, like in the Jetsons?Photo by Rob Wingate on Unsplash. It’s a dream of science fiction that harkens back to the Jetsons, or The Fifth Element; some sort of machine that produces food from nothing. And not just food — meat, tasty and delicious steaks, chicken, and pork, all without ever needing to go through the nasty business of raising and butchering an animal.
Related Contributors
InnoCan Pharma Reports Impressive Preclinical Trial Results as it Eyes Expansion into $52b Veterinary Services Industry
InnoCan Pharma Corporation, an Israeli pharmaceutical technology company and pioneer in CBD-Pharma delivery systems, reported positive results in a preclinical trial on epileptic seizures in dogs using LPT. The company is conducting this research in collaboration with Yissum, the commercial arm of The Hebrew University of Jerusalem.
MeaTech 3D is developing cultured meat to take customized food to the next level
An investment in the future of food ― meet the company that is going to enable the production of real delicious, nutritious meat that’s slaughter-free. MeaTech 3D (Nasdaq: MITC) is a global deep-tech food company developing the advanced biotechnology and engineering capabilities to produce delicious, nutritious real meat made from cells rather than slaughtered animals. The company has been advancing its bio-printing technology in order to circumvent unsustainable challenges faced by conventional animal husbandry, such as the industry’s enormous carbon footprint, water and land usage, and animal welfare issues. Importantly, MeaTech has just made an announcement confirming a significant upgrade to its technology that should help the company continue accelerating its progress toward commercialization.
Alameda biotech building bought for $150 million
(Arne Dedert - Pool / Getty Images) (ALAMEDA, Calif.) A large office building in Alameda currently leased by a rapidly expanding biotech company was recently purchased by a veteran commercial real estate investment firm.